Treatment with rIFN-γ has no effect on cardiac allograft rejection

J. N.M. Ijzermans; E. Bouwman; R. W.F. De Bruin; J. Jeekel; R. L. Marquet

Treatment with rIFN-γ has no effect on cardiac allograft rejection

J. N.M. Ijzermans^*, E. Bouwman, R. W.F. De Bruin, J. Jeekel, R. L. Marquet

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

7 Citations (Scopus)

Abstract

The effect of recombinant rat interferon-gamma (rRIFN-γ) on allograft rejection was studied in two rat heart transplantation models. Recipients were treated with rRIFN-γ by intraperitoneal or intravenous injection, either by bolus or continuous infusion. Treatment was started after transplantation and continued during a period ranging from 4 to 10 days; dosages varied from 2.5 x 10² U/kg/day to 3 x 10⁶ U/kg/day. Controls were infused with PBS. Treatment with rRIFN-γ had no effect on allograft survival, irrespective of the route of administration, the dosage used or the duration of treatment. Higher dosages of rRIFN-γ induced serious morbidity and mortality. In conclusion, systemic treatment of cardiac allograft recipients with rRIFN-γ has no effect on graft rejection and is associated with serious toxicity and mortality when high dosages are used.

Original language	English
Pages (from-to)	243-245
Number of pages	3
Journal	Immunology
Volume	73
Issue number	2
Publication status	Published - 1991

Cite this

@article{d0e2138519fc487f84b15e1b3919bcaa,

title = "Treatment with rIFN-γ has no effect on cardiac allograft rejection",

abstract = "The effect of recombinant rat interferon-gamma (rRIFN-γ) on allograft rejection was studied in two rat heart transplantation models. Recipients were treated with rRIFN-γ by intraperitoneal or intravenous injection, either by bolus or continuous infusion. Treatment was started after transplantation and continued during a period ranging from 4 to 10 days; dosages varied from 2.5 x 102 U/kg/day to 3 x 106 U/kg/day. Controls were infused with PBS. Treatment with rRIFN-γ had no effect on allograft survival, irrespective of the route of administration, the dosage used or the duration of treatment. Higher dosages of rRIFN-γ induced serious morbidity and mortality. In conclusion, systemic treatment of cardiac allograft recipients with rRIFN-γ has no effect on graft rejection and is associated with serious toxicity and mortality when high dosages are used.",

author = "Ijzermans, {J. N.M.} and E. Bouwman and {De Bruin}, {R. W.F.} and J. Jeekel and Marquet, {R. L.}",

year = "1991",

language = "English",

volume = "73",

pages = "243--245",

journal = "Immunology",

issn = "0019-2805",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "2",

}

TY - JOUR

T1 - Treatment with rIFN-γ has no effect on cardiac allograft rejection

AU - Ijzermans, J. N.M.

AU - Bouwman, E.

AU - De Bruin, R. W.F.

AU - Jeekel, J.

AU - Marquet, R. L.

PY - 1991

Y1 - 1991

N2 - The effect of recombinant rat interferon-gamma (rRIFN-γ) on allograft rejection was studied in two rat heart transplantation models. Recipients were treated with rRIFN-γ by intraperitoneal or intravenous injection, either by bolus or continuous infusion. Treatment was started after transplantation and continued during a period ranging from 4 to 10 days; dosages varied from 2.5 x 102 U/kg/day to 3 x 106 U/kg/day. Controls were infused with PBS. Treatment with rRIFN-γ had no effect on allograft survival, irrespective of the route of administration, the dosage used or the duration of treatment. Higher dosages of rRIFN-γ induced serious morbidity and mortality. In conclusion, systemic treatment of cardiac allograft recipients with rRIFN-γ has no effect on graft rejection and is associated with serious toxicity and mortality when high dosages are used.

AB - The effect of recombinant rat interferon-gamma (rRIFN-γ) on allograft rejection was studied in two rat heart transplantation models. Recipients were treated with rRIFN-γ by intraperitoneal or intravenous injection, either by bolus or continuous infusion. Treatment was started after transplantation and continued during a period ranging from 4 to 10 days; dosages varied from 2.5 x 102 U/kg/day to 3 x 106 U/kg/day. Controls were infused with PBS. Treatment with rRIFN-γ had no effect on allograft survival, irrespective of the route of administration, the dosage used or the duration of treatment. Higher dosages of rRIFN-γ induced serious morbidity and mortality. In conclusion, systemic treatment of cardiac allograft recipients with rRIFN-γ has no effect on graft rejection and is associated with serious toxicity and mortality when high dosages are used.

UR - http://www.scopus.com/inward/record.url?scp=0025874944&partnerID=8YFLogxK

M3 - Article

C2 - 1906427

AN - SCOPUS:0025874944

SN - 0019-2805

VL - 73

SP - 243

EP - 245

JO - Immunology

JF - Immunology

IS - 2

ER -

Treatment with rIFN-γ has no effect on cardiac allograft rejection

Abstract

Other files and links

Fingerprint

Cite this